Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor

January 1979
British Medical Journal;1/27/1979, Vol. 1 Issue 6158, p220
Academic Journal
Examines the improved metabolic profiles in insulin-treated diabetic patients administered with an alpha-glucosidehydrolase inhibitor. Effect of acarbose on postprandial increases in blood glucose; Reduction of glucose absorption rate; Fermentation of non-absorbed sugars.


Related Articles

  • Are 5-α Reductase Inhibitors Associated with Hip Fractures?  // Internal Medicine Alert;11/29/2008 Pharmacology Watch, p1 

    The article presents a discussion on reductase inhibitors and hip fracture in men, the effects of drug-reimbursement policy on outcomes, and the new guidelines for type 2 diabetes.

  • Dapagliflozin.  // Australian Prescriber;Oct2013, Vol. 36 Issue 5, p174 

    The article reports on the approval of medicine Dapagliflozin, a drug used to treat type 2 diabetes. It mentions that Dapagliflozin is the first sodium-glucose co-transporter inhibitor responsible for about 90 percent of the glucose reabsorption in the kidney. It states that blocking this...

  • Vildagliptin prevents hypos by affecting glucagon response. Owen, Olwen Glynn // British Journal of Hospital Medicine (17508460);Oct2008, Vol. 69 Issue 10, p554 

    The article reports on the study presented by Dr. Bo Ahren of Lund University in Sweden that demonstrates how vildagliptin, a class of DPP-4 inhibitors, lowers the blood sugar while avoiding hypoglycaemia in type 2 diabetes. It reveals that vildagliptin stimulates the alpha cells of pancreatic...

  • Glycogen synthase kinase 3: A key regulator of cellular fate. Forde, J. E.; Dale, T. C. // Cellular & Molecular Life Sciences;Aug2007, Vol. 64 Issue 15, p1930 

    The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified as a key regulator of insulin-dependent glycogen synthesis. GSK-3 was subsequently shown to function in a wide range of cellular processes including differentiation, growth, motility and apoptosis. Aberrant...

  • Our Children's "Diabesity" Epidemic. Miller, Doriane C. // Chicago Citizen - Chatham Southeast Edition;11/14/2012, Vol. 47 Issue 34, p2 

    The article focuses on the reasons of diabetes affecting the children. Factors causing obesity is considered the factors for increased Type 2 diabetes risk. Intake of meals with high sugar and fat contents but no vitamins or protein contents causes pancreas breakdown inhibiting the secretion of...

  • Treatment with BI 1356, a Novel and Potent DPP-IV Inhibitor, Significantly Reduces Glucose Excursions after an oGTT in Patients with Type 2 Diabetes. Heise, Tim; Tiessen, Renger; Huettner, Silke; Ring, Arne; Ritzhaupt, Armin; Graefe-Mody, Ulrike; Dugi, Klaus A. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA156 

    BI 1356 is a novel, potent, and selective DPP-IV inhibitor currently in development for type 2 diabetes. The safety, pharmacokinetics, and pharmacodynamic properties of BI 1356 were investigated in a randomised, double-blind, placebo-controlled study in patients with type 2 diabetes. Forty-seven...

  • The Cell Cycle Inhibitory Protein p21cip Is Not Essential for Maintaining β-Cell Cycle Arrest or β-Cell Function In Vivo. Cozar-Castellano, Irene; Haught, Marcia; Stewart, Andrew F. // Diabetes;Dec2006, Vol. 55 Issue 12, p3271 

    p21cip1, a regulatory molecule upstream of the G1/0 checkpoint, is increased in β-cells in response to mitogenic stimulation. Whereas p21cip1 can variably stimulate or inhibit cell cycle progression, in vitro studies suggest that p21cip1 acts as an inhibitor in the pancreatic β-cell. To...

  • Glycogen Synthase Kinase-3β and Cathepsin B in Diabetic Endothelial Progenitor Cell Dysfunction: An Old Player Finds a New Partner. Muniyappa, Ranganath; Sowers, James R. // Diabetes;Apr2014, Vol. 63 Issue 4, p1194 

    The authors reflect on a study by B. Hibbert and colleagues on the potency of glycogen synthase kinase-3β (GSK3β) inhibitors on diabetic patients' endothelial progenitor cells (D-EPCs). They cite the need for revascularization through surgery and endovascular to reestablish tissue function...

  • DPP-IV Inhibitors and GLP-1 Analogues Will Experience the Biggest Growth in Market Share of All Drug Classes in Type 2 Diabetes, Increasing from 20% in 2010 to 47% in 2020.  // Biomedical Market Newsletter;10/17/2011, Vol. 21, p604 

    The article presents a forecast regarding the market share condition of DPP-IV inhibitors and GLP-1 analogues for 2020. According to Decision Resources Inc., these type 2 diabetes treatments will increase its combined market share by 47%, equivalent to almost 45 billion U.S. dollars in the same...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics